Similarly, EVs derived from EGFR-specific and HER2-specific CAR-T cells are cytotoxic against breast cancer cells in vitro and in vivo, showing the advantage of lacking the expression of PD-1, so that they cannot be inhibited by the PD1-PD-L1 axis [161]. The gene discussed is ERBB2; the disease is breast carcinoma.